Showing results (461-470 of 757) with videos related to

Sort By:
Pageof 76
Kidney & Blood Pressure Research|October 8, 2023
Blood Pressure and Mortality in the 4D StudyBabak Yazdani, Marcus E Kleber, Graciela E Delgado, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 14, 2011
OPPORTUNITY™: a large-scale randomized clinical trial of growth hormone in hemodialysis patientsJoel D Kopple, Alfred K Cheung, Jens Sandahl Christiansen, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 11, 2019
The nephrology crystal ball: the medium-term futureCarmine Zoccali, Peter J Blankestijn, Annette Bruchfeld, et al.
Diabetes Research and Clinical Practice|March 22, 2022
Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary diseaseStefan D Anker, Leif-Erik Sander, David H Fitchett, et al.
Kidney International|May 3, 2014
Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global OutcomesMark E Molitch, Amanda I Adler, Allan Flyvbjerg, et al.
Kidney International|March 29, 2002
L-arginine deficiency and supplementation in experimental acute renal failure and in human kidney transplantationLothar Schramm, Mylinh La, Ekkehart Heidbreder, et al.
Kidney International|November 18, 2017
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammationBenjamin C Storey, Natalie Staplin, Richard Haynes, et al.
European Journal of Heart Failure|January 22, 2024
Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-PreservedTripti Rastogi, João Pedro Ferreira, Javed Butler, et al.
Atherosclerosis|August 25, 2015
Association of relative telomere length with cardiovascular disease in a large chronic kidney disease cohort: the GCKD studyJulia Raschenberger, Barbara Kollerits, Stephanie Titze, et al.
Clinical Kidney Journal|December 8, 2018
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY studyWilliam G Herrington, David Preiss, Richard Haynes, et al.
Pageof 76